Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · IEX Real-Time Price · USD
8.05
+0.45 (5.92%)
At close: May 2, 2024, 4:00 PM
8.04
-0.01 (-0.12%)
After-hours: May 2, 2024, 4:24 PM EDT
Pulse Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
444.56M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 700.00K | -718.00K | -50.63% |
Dec 31, 2021 | 1.42M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ZimVie | 457.43M |
CareDx | 280.32M |
Sonida Senior Living | 255.32M |
biote | 185.36M |
Theravance Biopharma | 57.42M |
PLSE News
- 23 hours ago - Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 - Business Wire
- 8 days ago - Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 - Business Wire
- 5 weeks ago - Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results - Business Wire
- 5 weeks ago - Pulse Biosciences Announces Plans to Initiate a Rights Offering - Business Wire
- 7 weeks ago - Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 - Business Wire
- 7 weeks ago - Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System - Business Wire
- 2 months ago - Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study - Business Wire
- 3 months ago - Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium - Business Wire